Overseas Net Profit grows by 86.51 percent for the year ended 31st March, 2010
Board of Directors recommends Annual Dividend of 25 percent
Bilcare Ltd. (BSE code: 526853), service provider to the global pharmaceutical industry posted an impressive performance for the year ended March 31st 2010.
The Consolidated Sales for the year ended March 31st 2010, stood at Rs.1047.83 Cr., showing a growth of 22.41 percent as against Rs.856.02 Cr. in the corresponding period of previous year, resulting in EBIDTA of Rs.259.92 Cr. and Net Profit of Rs.116.95 Cr., a growth of 33.83% in EBIDTA and 41.01% in Net Profit.
The Board of Directors of the Company at its meeting held on July 23, 2010, inter alia, has recommended a dividend of Rs. 2.50 per share for the year ended March 31, 2010 subject to the approval of the Members.
Also Read
Mr. Mohan Bhandari, Chairman & Managing Director, Bilcare Limited announced: “I am delighted to inform you about our steady state growth of established business in pharma packaging innovation and clinical supplies, equally exciting are prospects for our newly launched technology, which has now gone into execution for Delhi State Police Force. It is also being deployed in leading pharmaceutical and agrochemical companies in India. Internationally, this technology has been accepted by a leading wine producer in USA as well as by the Presidential security force of an Asian country. Bilcare is about to close a deal with a European consumer product company. On the document security front, a major trial is underway with a printer manufacturer in USA”.
The India Standalone Sales for the quarter end (Q4FY10) stood at Rs.145.71 Cr. as against Rs.121.86 Cr. in the same quarter of the previous year, showing a growth of 19.57%. This resulted in the EBITDA for India Standalone growing to Rs.47.01 Cr. from Rs.37.32 Cr. in the corresponding quarter of the previous year, showing a growth of 25.96%. India standalone Sales for the year ended 31st March 2010, stood at Rs.549.65 Cr. as against Rs.471.33 Cr. of the previous year. EBITDA and Net Profit for the year were at Rs.165.74 Cr. and Rs.75.47 Cr., registering a growth of 26.67 percent in EBIDTA and 24.33 percent in Net Profit.
Overseas Sales for the year ended March 31st 2010, stood at Rs.498.18 Cr. as against Rs.384.69 Cr. of the previous year, showing a growth of 29.50 percent. Similarly, EBIDTA and Net Profit for the year ended at Rs.94.18 Cr. and Rs.41.48 Cr. showing a growth of 48.62 percent in EBIDTA and 86.51 percent in Net Profit.
About Bilcare:
Bilcare is an internationally integrated service provider to the global pharmaceutical industry offering innovative pharma packaging & research, global clinical trial supplies services and anti-counterfeiting technologies for the pharmaceuticals; while Bilcare Technologies under its nonClonableID™ offers identification , authentication and secure track-n-trace technologies Bilcare operates state-of-the-art manufacturing and research facilities in India, Singapore, USA, UK and has regional offices in Brazil, Germany, China and Australia. Bilcare provides solutions that address many of the industry's key concerns including the Five Key concerns - (5 C's) viz. counterfeit, compliance, communication, convenience and cost.
